Birabaharan Morgan, Johns Scott T, Kaelber David C, Martin Thomas C S, Mehta Sanjay R
Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
San Diego Veterans Affairs Medical Center, San Diego, California, USA.
Clin Infect Dis. 2024 Dec 26. doi: 10.1093/cid/ciae649.
RSV vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention groups compared to control. In this large, population-based, propensity-matched study, we found RSV vaccine was not associated with increased risk of new-onset or recurrent atrial fibrillation within 1-42 days compared to influenza or Tdap vaccines.
呼吸道合胞病毒(RSV)疫苗临床试验报告称,与对照组相比,干预组心房颤动的发生率更高。在这项基于人群的大型倾向匹配研究中,我们发现与流感疫苗或破伤风、白喉和无细胞百日咳(Tdap)疫苗相比,RSV疫苗在1至42天内与新发或复发性心房颤动风险增加无关。